Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037421 | 0.82 | BCL2 (0.41) | PIK3CDBCL2GRM5 | |
| SCHEMBL2035181 | 0.82 | PIK3CD (0.40) | PIK3CDBCL2GRM5 | |
| SCHEMBL12470347 | 0.79 | PIK3CD (0.38) | PIK3CDBCL2 | |
| SCHEMBL15621559 | 0.79 | PIK3CD (0.38) | PIK3CDBCL2 | |
| SCHEMBL2017931 | 0.79 | SLC22A12 (0.41) | PIK3CDBCL2PTGS2SCN9AGRM5 | |
| SCHEMBL15617777 | 0.77 | BCL2 (0.38) | PIK3CDBCL2 | |
| SCHEMBL2041671 | 0.73 | ACLY (0.36) | PTGS2SCN9AGRM5CYP2C9 | |
| SCHEMBL2018513 | 0.73 | NT5E (0.38) | GRM5 | |
| SCHEMBL2039744 | 0.72 | NT5E (0.36) | PIK3CDSCN9AGRM5 | |
| SCHEMBL2018303 | 0.71 | PIK3CD (0.41) | PIK3CDBCL2PTGS2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | PIK3CD 13/4885BCL2 1174/4885PTGS2 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.